Trevi Therapeutics enters its May 7 earnings release with a meaningful short base still in place, even as the stock has rebounded sharply and the lending market suggests bears are not pressing harder.
Short sellers remain committed. At 12.3% of the free float, short interest is elevated for a small-cap biotech — and it has edged up 3.2% over the past week. That said, the wider trend tells a different story: short interest is down roughly 6% from a month ago, when bears were more aggressively positioned. Borrow costs are low at 0.44%, having eased about 9% over the past week. Availability is ample, with the lending pool showing no signs of stress. Taken together, this looks like a short base that has stabilised rather than one that is building into the print.
The bull-bear divide here turns almost entirely on clinical execution. Bulls point to Haduvio as a potential first-in-class therapy across multiple indications, with a funding runway extending into 2028 and clinical data that has reduced binary risk. The Morgan Stanley analyst trimmed the target to $18 after the March earnings release but kept an Overweight rating — a signal the firm sees the risk-reward as intact even after a modest disappointment. Needham went the other direction on the same day, raising its target to $24. The consensus now clusters around $21.91 against the current price of $14.66, implying the Street sees roughly 49% upside from here. Bears focus on the clock: GSK's camlipixant phase 3 data expected in Q3 2026 represents a competitive read-through that could reshape the market narrative, and the large IPF cough phase 3 programme still needs additional financing. The EPS picture adds colour — the 30-day momentum score ranks in the 72nd percentile, though full-year forward estimates are trending sharply negative, a reminder that TRVI remains pre-revenue.
Options positioning offers a modest read on sentiment. The put/call ratio has climbed to 0.45, above its 20-day average of 0.36 but only about one standard deviation higher — cautious, not alarmed. Peers have largely moved in the same direction: RAPP and ARVN are each up around 4-5% on the week, and TARS is up 4.8%, suggesting sector tailwinds rather than TRVI-specific momentum driving the 22% one-month gain to $14.66. Among institutional holders, Fidelity (FMR LLC) added 3.2 million shares as of March 31, one of the larger recent builds, while Rubric Capital and Viking Global each trimmed by over 1.9 million shares in Q4 2025.
Thursday's print will test whether the company can point to enough Phase 3 progress on Haduvio — and provide enough clarity on the IPF financing path — to justify a multiple that has expanded sharply even as the forward earnings trajectory remains deeply negative.
See the live data behind this article on ORTEX.
Open TRVI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
